SAN Sanofi

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

PARIS, France – March 4, 2021 - Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).

These documents are available on the company’s website: .

In addition, the Form 20-F is available on the website of the SEC () and the “Document d’Enregistrement Universel” is available on the website of the AMF (). A hard copy of these documents, each of which contains our complete audited financial statements, may be received free of charge, upon request.

 



About Sanofi



 



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



 



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



 



Sanofi, Empowering Life



 





Media Relations Contact

Ashleigh Koss

Tel: +1 (908) 981-8745





 



Sandrine Guendoul

Tel.: +33 (0)1 53 77 46 46









 
 



Investor Relations Contacts Paris

Eva Schaefer-Jansen

Arnaud Delepine

Yvonne Naughton



 



Investor Relations Contacts North America

Felix Lauscher

Fara Berkowitz

Suzanne Greco



 



IR main line:

Tel.: +33 (0)1 53 77 45 45





 







 



Attachment



EN
04/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - August 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry un...

 PRESS RELEASE

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions au...

Emira Sagaama ... (+4)
  • Emira Sagaama
  • Oddo Sustainability Team
  • Stephane Beyazian
  • Thomas Zlowodzki
Emira Sagaama ... (+4)
  • Emira Sagaama
  • Oddo Sustainability Team
  • Stephane Beyazian
  • Thomas Zlowodzki
 PRESS RELEASE

Press Release: Sanofi’s SAR402663 earns fast track designation in the ...

Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for people living with neovascular age-related macular degenerationNeovascular or “wet” age-related macular degeneration can lead to significant vision loss and affects more than one million people in the US Paris, September 11, 2025. The US Food and Dr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch